Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 8, 2025

Primary Completion Date

December 31, 2029

Study Completion Date

December 31, 2029

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

Healthy Donor Fecal Microbiota Transplant (hdFMT)

FMT is a procedure in which fecal matter or stool is collected from a tested donor, mixed with a saline or other solution, strained and infused into the colon by performing a colonoscopy and sigmoidoscopy, or, administered orally in the form of capsules. The FMT consists of introducing normal bacterial flora contained in the stool collected from a healthy donor into the small intestine. In this case, the hdFMT will be administered on Cycle 1 Day 1 and Cycle 3 Day 1 during Treatment Phase 1 and every 9 weeks starting with Cycle 4 Day 1 during Treatment Phase 2.

DRUG

Pembrolizumab

Pembrolizumab, 200mg, will be administered as a 30-minute IV infusion every 3 weeks starting Cycle 1 Day 1 (same day as the FMT), and continue on Day 1 of each 21-day cycle.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

Gateway for Cancer Research

OTHER

lead

Diwakar Davar

OTHER